

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-32. (Cancelled)

33. (Previously presented) An expression vector comprising:  
a transcriptional start site;  
a promoter operably linked to the transcriptional start site; and  
an enhancer operably linked to the promoter, the enhancer comprising a nucleotide sequence of SEQ. ID NO:1 or its complement;  
wherein the expression vector is a viral vector.

34. (Previously presented) The expression vector of claim 33, wherein the promoter drives transcription of an mRNA.

35. (Previously presented) The expression vector of claim 34, wherein the mRNA encodes a growth hormone.

36. (Previously presented) The expression vector of claim 33, wherein the promoter is a  $\zeta$ -promoter.

37. (Previously presented) The expression vector of claim 33, wherein the nucleotide sequence is SEQ ID NO:2 or its complement.

38. (Previously presented) The expression vector of claim 37, wherein the promoter is a  $\zeta$ -promoter.

39. (Previously presented) The expression vector of claim 33, wherein the nucleotide sequence is SEQ ID NO:3 or its complement.

40. (Previously presented) The expression vector of claim 39, wherein the promoter is a  $\zeta$ -promoter.

41. (Previously presented) The expression vector of claim 33, wherein the expression vector is a retroviral vector.

42. (Previously presented) The expression vector of claim 41, wherein the promoter drives transcription of an mRNA.

43. (Previously presented) The expression vector of claim 42, wherein the mRNA encodes a growth hormone.

44. (Previously presented) The expression vector of claim 41, wherein the promoter is a  $\zeta$ -promoter.

45. (Previously presented) The expression vector of claim 44, wherein the promoter drives transcription of an mRNA.

46. (Previously presented) The expression vector of claim 45, wherein the mRNA encodes a growth hormone.

47. (Previously presented) The expression vector of claim 41, wherein the nucleotide sequence is SEQ ID NO:2 or its complement.

48. (Previously presented) The expression vector of claim 47, wherein the promoter is a  $\zeta$ -promoter.

49. (Previously presented) The expression vector of claim 41, wherein the nucleotide sequence is SEQ ID NO:3 or its complement.

50. (Previously presented) The expression vector of claim 49, wherein the promoter is a  $\zeta$ -promoter.

51. (Previously presented) A method of expressing a transcript in an isolated cell, the method comprising introducing a viral expression vector into the cell, the expression vector including:

a transcriptional start site;

a nucleic acid sequence operably linked to the transcriptional start site, the nucleic acid sequence encoding the transcript;

a promoter operably linked to the transcriptional start site; and

an enhancer operably linked to the promoter, the enhancer having a nucleotide sequence of SEQ. ID NO:1 or its complement.

52. (Previously presented) The method of claim 51, wherein the promoter drives transcription of an mRNA.

53. (Previously presented) The method of claim 51, wherein the promoter is a  $\zeta$ -promoter.

54. (Previously presented) The method of claim 51, wherein the nucleotide sequence is SEQ ID NO:2 or its complement.

55. (Previously presented) The method of claim 54, wherein the promoter is a  $\zeta$ -promoter.

56. (Previously presented) The method of claim 51, wherein the nucleotide sequence is SEQ ID NO:3 or its complement.

57. (Previously presented) The method of claim 56, wherein the promoter is a  $\zeta$ -promoter.

58. (Previously presented) The method of claim 51, wherein the expression vector is a retroviral vector.

59. (Previously presented) The method of claim 58, wherein the promoter is a  $\zeta$ -promoter.

60. (Previously presented) The method of claim 58, wherein the nucleotide sequence is SEQ ID NO:2 or its complement.

61. (Previously presented) The method of claim 60, wherein the promoter is a  $\zeta$ -promoter.

62. (Previously presented) The method of claim 58, wherein the nucleotide sequence is SEQ ID NO:3 or its complement.

Applicant : Chen-Kun James Shen  
Serial No. : 09/977,432  
Filed : October 15, 2001  
Page : 6 of 10

Attorney's Docket No.: 08919-016003 / 13A-870916  
(CON)

63. (Previously presented) The method of claim 62, wherein the promoter is a  $\zeta$ -promoter.